/
A New Type of Biopharmaceutical Company BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
$67.45
$0.64 (-0.94%)
Price from 27 days ago
The business is unprofitable at the operating level (-104.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 126.3% YoY with margins expanding 163.0pp.
Negative free cash flow of -$447M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$580M
▲ +126.3% YoY
Net Income (TTM)
-$722M
▼ -35.3% YoY
Op. Margin
-90.52%
▲ +163.0pp YoY
ROIC
-24.71%
▲ +69.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$445M
▲ +14.3% YoY
Op. Cash Flow (TTM)
-$444M
▲ +14.4% YoY
Net Debt
$1.73B
Cash & Equiv.
$940M
5Y CAGR: +127.4%
Continue Research